We are live on ! Find out more
FCMI

Foresite Capital Management II Portfolio holdings

AUM $29.2M
1-Year Est. Return 44.84%
This Fund
S&P 500
This Quarter Est. Return
+4.76%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$298M
AUM Growth
-$31.1M
Cap. Flow
-$7.8M
Cap. Flow %
-2.62%
Top 10 Hldgs %
83.41%
Holding
29
New
–
Increased
9
Reduced
7
Closed
5

Top Buys

Rank Stock Value
1
LRMR icon
Larimar Therapeutics
LRMR
+$9.06M
2
OREX
Orexigen Therapeutics, Inc.
OREX
+$4.77M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$2.54M
4
EPZM
Epizyme, Inc
EPZM
+$2.22M
5
NVET
Nexvet Biopharma plc Ordinary Shares
NVET
+$654K

Top Sells

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$12.2M
2
AERI
Aerie Pharmaceuticals
AERI
+$3.92M
3
XLRN
Acceleron Pharma
XLRN
+$2.2M
4
QTNT
Quotient Limited Ordinary Shares
QTNT
+$1.37M
5
BITI
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
+$1.06M

Sector Composition

Rank Sector Weight
1 Healthcare 65.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RGLS
26
PUT
DELISTED
Regulus Therapeutics
RGLS
– –
-2,083
Closed -$1.64M
EPZM
27
PUT
DELISTED
Epizyme, Inc
EPZM
– –
-150,000
Closed -$1.93M
BITI
28
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
– –
-80,883
Closed -$1.06M
OREX
29
CALL
DELISTED
Orexigen Therapeutics, Inc.
OREX
– –
-8,500
Closed -$179K
1
2

Similar funds

AG
Appleton Group Appleton, Wisconsin $28.6M AUM 32.21% 1-Year Est. Return
SAM
Sandbar Asset Management London, United Kingdom $30.5M AUM 46.07% 1-Year Est. Return
AC
Amia Capital London, United Kingdom $32.1M AUM 0.56% 1-Year Est. Return
QI
Qualcomm Inc San Diego, California $32.1M AUM 5.35% 1-Year Est. Return
TAAM
Top Ace Asset Management Hong Kong $25.3M AUM 23.27% 1-Year Est. Return
NAM
Nationwide Asset Management Columbus, Ohio $25.1M AUM 13.37% 1-Year Est. Return
MSKCC
Memorial Sloan Kettering Cancer Center New York $24.6M AUM 10.16% 1-Year Est. Return
BRC
Bishop Rock Capital New York $24.3M AUM 20.73% 1-Year Est. Return

Foresite Capital Management II's Q4 2015 Portfolio in Review

As of Q4 2015, Foresite Capital Management II held 29 positions worth $298M, down 9.4% from $329M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Foresite Capital Management II's Q4 2015 filing shows 9 increased, 7 reduced and 5 closed positions. The largest sale was Chinook Therapeutics, Inc. Common Stock, an estimated $12.2M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 58% a quarter earlier.

  • Foresite Capital Management II added most to Larimar Therapeutics in Q4 2015, an estimated $9.06M increase.
  • Foresite Capital Management II's biggest Q4 2015 reduction was Chinook Therapeutics, Inc. Common Stock, cutting an estimated $12.2M.
  • Foresite Capital Management II fully exited BIOTIE THERAPIES CORP SPONSORED ADR in Q4 2015, selling an estimated $1.06M.
  • Foresite Capital Management II's ten largest holdings make up 83% of its $298M portfolio in Q4 2015.
  • Foresite Capital Management II opened 0 new positions and closed 5 in Q4 2015.
  • Foresite Capital Management II's portfolio value fell 9.4% quarter-over-quarter to $298M.

Based on Foresite Capital Management II's 13F filing for Q4 2015, filed 12 Feb 2016.